oxymorphone

Therapeutic Classification: opioid analgesics

Pharmacologic Classification: opioid agonists

High Alert

Acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Binds to opiate receptors in the CNS.
Alters the perception of and response to painful stimuli while producing generalized CNS depression.

Therapeutic effects:

Decrease in pain.

Absorption: 10% absorbed following oral administration. Food and alcohol significantly ↑ absorption (38%).

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Mostly metabolized by the liver; at least 2 metabolites are pharmacologically active, <1% excreted unchanged in urine.

Half-Life: 2.6–4 hr.

(analgesic effects)

ROUTE	ONSET	PEAK	DURATION
PO	unknown	unknown	4–6 hr

Contraindicated in:

Hypersensitivity;
Concurrent alcohol;
Moderate or severe hepatic impairment;
Significant respiratory depression (unless monitoring and resuscitative equipment are readily available);
Acute or severe bronchial asthma (unless monitoring and resuscitative equipment are readily available);
Paralytic ileus.

Use Cautiously in:

Personal or family history of substance use disorder or mental illness;
Acute alcoholism or delirium tremens or other toxic psychoses;
Mild hepatic impairment;
Head injury/↑ intracranial pressure (may obscure neurologic signs and further ↑ pressure);
Volume depletion or drugs that may cause hypotension including diuretics and phenothiazines (↑ risk of severe hypotension);
Circulatory shock (may ↑ risk of severe hypotension);
Adrenocortical insufficiency;
Seizure disorders;
Hypothyroidism;
Prostatic hypertrophy or ureteral stricture;
Severe pulmonary impairment;
Renal impairment (CCr <50 mL/min);
Biliary tract disease or pancreatitis;
OB: Avoid chronic use; prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome;
Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant;
Pedi: Safety and effectiveness not established in children;
Geri: risk of respiratory depression in older adults; dose suggested.

Conditions association with hypoxia, hypercapnea, ↓ respiratory reserve (including asthma, COPD, cor pulmonale, morbid obesity, sleep apnea, myxedema, kyphoscoliosis, CNS depression, and coma).

CV: orthostatic hypotension

Derm: flushing, sweating

EENT: blurred vision, diplopia, miosis

Endo: adrenal insufficiency

GI: constipation, dry mouth, nausea, vomiting

GU: urinary retention

Neuro: confusion, sedation, dizziness, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams, confusion, sedation, dizziness, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams

Resp: RESPIRATORY DEPRESSION (INCLUDING CENTRAL SLEEP APNEA AND SLEEP-RELATED HYPOXEMIA)

Misc: allodynia, opioid-induced hyperalgesia, physical dependence, psychological dependence, tolerance

Drug-drug:

Use with caution in patients receiving MAO inhibitors (may result in unpredictable reactions; ↓ initial dose of oxymorphone to 25% of usual dose).
Use with benzodiazepines or other CNS depressants, including other opioids, nonbenzodiazepine sedative/hypnotics, anxiolytics, general anesthetics, muscle relaxants, antipsychotics, and alcohol, may cause profound sedation, respiratory depression, coma, and death; reserve concurrent use for when alternative treatment options are inadequate.
Alcohol may ↑ levels and ↑ the risk of toxicity.
Drugs that may cause volume depletion or hypotension, including diuretics and phenothiazines, may ↑ risk of severe hypotension.
Administration of partial-antagonist opioid analgesics may precipitate withdrawal in physically dependent patients.
Nalbuphine or buprenorphine↓ analgesia.
Drugs that affect serotonergic neurotransmitter systems, including tricyclic antidepressants, SSRIs, SNRIs, MAO inhibitors, TCAs, tramadol, trazodone, mirtazapine, 5-HT3 receptor antagonists, linezolid, methylene blue, and triptans, ↑ risk of serotonin syndrome.

Drug-Natural Products:

Concomitant use of kava-kava, valerian, or chamomile can ↑ CNS depression.

Larger doses may be required during chronic therapy
PO (Adults ): Opioid-naive patients: 10–20 mg (of immediate release [IR]) every 4–6 hr as needed; some patients may require initial dose of 5 mg, not to exceed 20 mg. For extended release (ER), give 5 mg every 12 hr; may titrate in increments of 5–10 mg every 12 hr every 3–7 days.

(Generic available)

Immediate-release tablets : 5 mg; 10 mg
Extended-release tablets: 5 mg; 7.5 mg; 10 mg; 15 mg; 20 mg; 30 mg; 40 mg

Assess type, location, and intensity of pain prior to and 1 hr following oral dose. When titrating opioid doses, ↑ of 25–50% should be administered until there is either a 50% ↓ in the patient’s pain rating on a numerical or visual analogue scale or the patient reports satisfactory pain relief. A repeat dose can be safely administered at the time of the peak if previous dose is ineffective and side effects are minimal.
Patients taking ER tablets should also be given supplemental short-acting opioid doses for breakthrough pain.
An equianalgesic chart (see Equianalgesic Dosing Guidelines) should be used when changing routes or when changing from one opioid to another.
Assess BP, HR, and respiratory rate before and periodically during administration. If respiratory rate <10/min, assess level of sedation. Physical stimulation may be sufficient to prevent significant hypoventilation. Dose may need to be ↓ by 25–50%. Initial drowsiness will ↓ with continued use. Monitor for respiratory depression, especially during initiation or following dose ↑; serious, life-threatening, or fatal respiratory depression may occur. May cause sleep-related breathing disorders (central sleep apnea, sleep-related hypoxemia).
Prolonged use may lead to physical and psychological dependence and tolerance. This should not prevent patient from receiving adequate analgesia. Most patients who receive oxymorphone for pain do not develop psychological dependence. Progressively higher doses may be required to relieve pain with long-term therapy.
Assess bowel function routinely. Prevention of constipation should be instituted with ↑ intake of fluids and bulk and laxatives. Stimulant laxatives should be administered routinely if opioid use exceeds 2–3 days, unless contraindicated. Consider drugs for opioid induced constipation.
Assess risk for opioid addiction, abuse, or misuse prior to administration. Abuse or misuse of ER preparations by crushing, chewing, snorting, or injecting dissolved product will result in uncontrolled delivery of oxymorphone and can result in overdose and death.

Lab Test Considerations:

May ↑ plasma amylase and lipase levels.

Toxicity and Overdose:

If an opioid antagonist is required to reverse respiratory depression or coma, naloxone is the antidote. Dilute the 0.4-mg ampule of naloxone in 10 mL of 0.9% NaCl and administer 0.5 mL (0.02 mg) by IV push every 2 min. For children and patients weighing <40 kg, dilute 0.1 mg of naloxone in 10 mL of 0.9% NaCl for a concentration of 10 mcg/mL and administer 0.5 mcg/kg every 2 min. Titrate dose to avoid withdrawal, seizures, and severe pain.

Accidental overdose of opioid analgesics has resulted in fatalities. Before administering, clarify all ambiguous orders.
Do not confuse oxymorphone with hydromorphone, oxybutynin, oxycodone, or Oxycontin.
Explain therapeutic value of medication prior to administration to enhance the analgesic effect.
- Regularly administered doses may be more effective than as needed administration. Analgesic is more effective if given before pain becomes severe.
- Coadministration with nonopioid analgesics may have additive analgesic effects and may permit lower doses.
- Medication should be discontinued gradually after long-term use to prevent withdrawal symptoms. For patients on long-acting agents who are physically opioid-dependent, initiate the taper by a small enough increment (no greater than 10%–25% of total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2–4 wk. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper. Monitor frequently to manage pain and withdrawal symptoms (restlessness; lacrimation; rhinorrhea; yawning; perspiration; chills; myalgia; mydriasis; irritability; anxiety; backache; joint pain; weakness; abdominal cramps; insomnia; nausea; anorexia; vomiting; diarrhea; or ↑ BP, respiratory rate, or HR). If withdrawal symptoms occur, pause the taper for a period of time or ↑ the dose of opioid analgesic to the previous dose, and then proceed with a slower taper. Also, monitor patients for changes in mood, emergence of suicidal thoughts, or use of other substances. A multimodal approach to pain management may optimize the treatment of chronic pain and assist with the successful tapering of the opioid analgesic.
FDA strongly encourages health care professionals to complete a REMS-compliant education program that includes all the elements of the FDA Education Blueprint for Health Care Providers Involved in the Management or Support of Patients with Pain, available at www.fda.gov/OpioidAnalgesicREMSBlueprint. Information on programs can be found at 1-800-503-0784 or www.opioidanalgesicrems.com.
Discuss availability of naloxone for emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing therapy, especially if patient has household members (including children) or other close contacts at risk for accidental exposure or overdose. Consider prescribing naloxone, based on the patient’s risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. However, the presence of risk factors for overdose should not prevent the proper management of pain in any patient.
PO: Administer at least 1 hr prior to or 2 hr after eating.Oxymorphone 5 mg and 10 mg tablets are available as both IR and ER; it is important to ensure that the correctly ordered tablet is administered to the patient.
Extended Release: DNC: Swallow ER tablets whole; do not break, crush, or chew. Titrate to mild to no pain with regular use of no more than 2 doses of supplemental analgesia (rescue) per 24 hr. Taking broken, chewed, crushed or dissolved ER tablets may lead to rapid release and absorption of a potentially fatal dose of oxymorphone.Dose of ER products should be based on 24-hr opioid requirement determined with short-acting opioids then converted to ER form.
- If patient is opioid-naive, start with 5 mg every 12 hr; then titrate in increments of 5–10 mg every 12 hr every 3–7 days to a level that provides adequate analgesia with minimal side effects.
- If converting from short-acting (IR) oxymorphone to ER oxymorphone, administer half the patient's total daily dose of short-acting (IR) oxymorphone as ER oxymorphone every 12 hr.
- Do not use ER oxymorphone for administration via nasogastric, gastric, or other feeding tubes, as it may cause obstruction of feeding tubes.
- If converting from other opioids, 10 mg of oral oxymorphone is equianalgesic to hydrocodone 20 mg, oxycodone 20 mg, methadone 20 mg, and morphine 30 mg orally.

Explain purpose and side effects of oxymorphone to patient. Instruct them to take medication as directed and when to ask for pain medication. Do not share medication with others, even if they have similar symptoms; may be harmful and is against the law. Keep out of children's reach. Advise patient to read Patient Informationbefore starting and with each Rx refill in case of changes.
Instruct patient to take oxymorphone as directed and not to adjust dose without consulting health care professional. Take missed doses as soon as possible if on chronic therapy. If almost time for next dose, skip dose and return to regular schedule. Do not double doses unless advised by health care professional. Do not stop taking oxymorphone abruptly; may cause withdrawal symptoms. Discontinue gradually under supervision of health care professional. Discuss safe use, risks, and proper storage and disposal of opioid analgesics with patients and caregivers with each Rx. The Patient Counseling Guide is available at www.fda.gov/OpioidAnalgesicREMSPCG.
Advise patient that oxymorphone is a drug with known abuse potential. Protect it from theft, and never give to anyone other than the individual for whom it was prescribed. Store out of sight and reach of children, and in a location not accessible by others.
Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose. Inform patients and caregivers about various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (Rx, direct from pharmacist, or state programs). OTC naloxone nasal spray is available at pharmacies nationwide for overdose or accidental ingestion.
Advise patient to notify health care professional if pain control is not adequate or if severe or persistent side effects occur.
Medication may cause drowsiness or dizziness. Advise patient to call for assistance when ambulating and to avoid driving or other activities that require alertness until response to the medication is known.
Advise patient to make position changes slowly to minimize orthostatic hypotension.
Advise patient to avoid concurrent use of alcohol or other CNS depressants with this medication.
Emphasize the importance of aggressive prevention of constipation with the use of oxymorphone.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
Encourage patient to turn, cough, and breathe deeply every 2 hr to prevent atelectasis.
Inform patients taking ER oxymorphone tablets that a soft mass resembling tablets may appear in stool; active medication was already absorbed.
Advise patient that good oral hygiene, frequent mouth rinses, and sugarless gum or candy may ↓ dry mouth.
Rep: Advise patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding. Inform patient of potential for neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Monitor neonate for signs and symptoms of withdrawal symptoms (irritability, hyperactivity and abnormal sleep pattern, high-pitched cry, tremor, vomiting, diarrhea, failure to gain weight); usually occur the first days after birth. Monitor infants exposed to oxymorphone through breast milk for excess sedation and respiratory depression. Chronic use may fertility in females and males.

Decrease in severity of pain without a significant alteration in level of consciousness or respiratory status.

NDC Code

0054- West-Ward Pharmaceuticals Corp.
- 0054-0283- Oxymorphone Hydrochloride
  - 0054-0283-25- 100 TABLET in 1 BOTTLE (0054-0283-25)

0054- West-Ward Pharmaceuticals Corp.
- 0054-0284- Oxymorphone Hydrochloride
  - 0054-0284-25- 100 TABLET in 1 BOTTLE (0054-0284-25)

0115- Impax Generics
- 0115-1231- Oxymorphone hydrochloride
  - 0115-1231-01- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1231-01)

0115- Impax Generics
- 0115-1231- Oxymorphone hydrochloride
  - 0115-1231-03- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1231-03)

0115- Impax Generics
- 0115-1231- Oxymorphone hydrochloride
  - 0115-1231-08- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1231-08)

0115- Impax Generics
- 0115-1231- Oxymorphone hydrochloride
  - 0115-1231-13- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1231-13)

0115- Impax Generics
- 0115-1232- Oxymorphone hydrochloride
  - 0115-1232-01- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1232-01)

0115- Impax Generics
- 0115-1232- Oxymorphone hydrochloride
  - 0115-1232-03- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1232-03)

0115- Impax Generics
- 0115-1232- Oxymorphone hydrochloride
  - 0115-1232-08- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1232-08)

0115- Impax Generics
- 0115-1232- Oxymorphone hydrochloride
  - 0115-1232-13- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1232-13)

0115- Impax Generics
- 0115-1233- Oxymorphone hydrochloride
  - 0115-1233-01- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1233-01)

0115- Impax Generics
- 0115-1233- Oxymorphone hydrochloride
  - 0115-1233-03- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1233-03)

0115- Impax Generics
- 0115-1233- Oxymorphone hydrochloride
  - 0115-1233-08- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1233-08)

0115- Impax Generics
- 0115-1233- Oxymorphone hydrochloride
  - 0115-1233-13- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1233-13)

0115- Impax Generics
- 0115-1234- Oxymorphone hydrochloride
  - 0115-1234-01- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1234-01)

0115- Impax Generics
- 0115-1234- Oxymorphone hydrochloride
  - 0115-1234-03- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1234-03)

0115- Impax Generics
- 0115-1234- Oxymorphone hydrochloride
  - 0115-1234-08- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1234-08)

0115- Impax Generics
- 0115-1234- Oxymorphone hydrochloride
  - 0115-1234-13- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1234-13)

0115- Impax Generics
- 0115-1315- Oxymorphone hydrochloride
  - 0115-1315-01- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1315-01)

0115- Impax Generics
- 0115-1315- Oxymorphone hydrochloride
  - 0115-1315-03- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1315-03)

0115- Impax Generics
- 0115-1315- Oxymorphone hydrochloride
  - 0115-1315-08- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1315-08)

0115- Impax Generics
- 0115-1315- Oxymorphone hydrochloride
  - 0115-1315-13- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1315-13)

0115- Impax Generics
- 0115-1316- Oxymorphone hydrochloride
  - 0115-1316-01- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1316-01)

0115- Impax Generics
- 0115-1316- Oxymorphone hydrochloride
  - 0115-1316-03- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1316-03)

0115- Impax Generics
- 0115-1316- Oxymorphone hydrochloride
  - 0115-1316-08- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1316-08)

0115- Impax Generics
- 0115-1316- Oxymorphone hydrochloride
  - 0115-1316-13- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1316-13)

0115- Impax Generics
- 0115-1317- Oxymorphone hydrochloride
  - 0115-1317-01- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1317-01)

0115- Impax Generics
- 0115-1317- Oxymorphone hydrochloride
  - 0115-1317-03- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1317-03)

0115- Impax Generics
- 0115-1317- Oxymorphone hydrochloride
  - 0115-1317-08- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1317-08)

0115- Impax Generics
- 0115-1317- Oxymorphone hydrochloride
  - 0115-1317-13- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0115-1317-13)

0406- SpecGx LLC
- 0406-1009- OXYMORPHONE HYDROCHLORIDE
  - 0406-1009-01- 100 TABLET in 1 BOTTLE (0406-1009-01)

0406- SpecGx LLC
- 0406-1010- OXYMORPHONE HYDROCHLORIDE
  - 0406-1010-01- 100 TABLET in 1 BOTTLE (0406-1010-01)

10702- KVK-Tech, Inc.
- 10702-070- Oxymorphone Hydrochloride
  - 10702-070-01- 100 TABLET in 1 BOTTLE (10702-070-01)

10702- KVK-Tech, Inc.
- 10702-070- Oxymorphone Hydrochloride
  - 10702-070-06- 60 TABLET in 1 BOTTLE (10702-070-06)

10702- KVK-Tech, Inc.
- 10702-071- Oxymorphone Hydrochloride
  - 10702-071-01- 100 TABLET in 1 BOTTLE (10702-071-01)

10702- KVK-Tech, Inc.
- 10702-071- Oxymorphone Hydrochloride
  - 10702-071-06- 60 TABLET in 1 BOTTLE (10702-071-06)

13107- Aurolife Pharma, LLC
- 13107-103- Oxymorphone Hydrochloride
  - 13107-103-01- 100 TABLET in 1 BOTTLE (13107-103-01)

13107- Aurolife Pharma, LLC
- 13107-103- Oxymorphone Hydrochloride
  - 13107-103-30- 30 TABLET in 1 BOTTLE (13107-103-30)

13107- Aurolife Pharma, LLC
- 13107-103- Oxymorphone Hydrochloride
  - 13107-103-99- 1000 TABLET in 1 BOTTLE (13107-103-99)

13107- Aurolife Pharma, LLC
- 13107-104- Oxymorphone Hydrochloride
  - 13107-104-01- 100 TABLET in 1 BOTTLE (13107-104-01)

13107- Aurolife Pharma, LLC
- 13107-104- Oxymorphone Hydrochloride
  - 13107-104-30- 30 TABLET in 1 BOTTLE (13107-104-30)

13107- Aurolife Pharma, LLC
- 13107-104- Oxymorphone Hydrochloride
  - 13107-104-99- 1000 TABLET in 1 BOTTLE (13107-104-99)

31722- Camber Pharmaceuticals Inc
- 31722-929- OXYMORPHONE HYDROCHLORIDE
  - 31722-929-01- 100 TABLET in 1 BOTTLE (31722-929-01)

31722- Camber Pharmaceuticals Inc
- 31722-930- OXYMORPHONE HYDROCHLORIDE
  - 31722-930-01- 100 TABLET in 1 BOTTLE (31722-930-01)

35356- Lake Erie Medical DBA Quality Care Products LLC
- 35356-967- Oxymorphone Hydrochloride
  - 35356-967-30- 30 TABLET in 1 BOTTLE (35356-967-30)

35356- Lake Erie Medical DBA Quality Care Products LLC
- 35356-968- Oxymorphone Hydrochloride
  - 35356-968-01- 120 TABLET in 1 BOTTLE (35356-968-01)

35356- Lake Erie Medical DBA Quality Care Products LLC
- 35356-968- Oxymorphone Hydrochloride
  - 35356-968-30- 30 TABLET in 1 BOTTLE (35356-968-30)

35356- Lake Erie Medical DBA Quality Care Products LLC
- 35356-968- Oxymorphone Hydrochloride
  - 35356-968-60- 60 TABLET in 1 BOTTLE (35356-968-60)

42806- Epic Pharma, LLC
- 42806-330- Oxymorphone Hydrochloride
  - 42806-330-01- 100 TABLET in 1 BOTTLE (42806-330-01)

42806- Epic Pharma, LLC
- 42806-331- Oxymorphone Hydrochloride
  - 42806-331-01- 100 TABLET in 1 BOTTLE (42806-331-01)

55700- Lake Erie Medical DBA Quality Care Products LLC
- 55700-215- Oxymorphone hydrochloride
  - 55700-215-30- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (55700-215-30)

55700- Lake Erie Medical DBA Quality Care Products LLC
- 55700-215- Oxymorphone hydrochloride
  - 55700-215-60- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (55700-215-60)

55700- Lake Erie Medical DBA Quality Care Products LLC
- 55700-387- Oxymorphone hydrochloride
  - 55700-387-60- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (55700-387-60)

55700- Lake Erie Medical DBA Quality Care Products LLC
- 55700-423- Oxymorphone hydrochloride
  - 55700-423-30- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (55700-423-30)

55700- Quality Care Products, LLC
- 55700-788- Oxymorphone hydrochloride
  - 55700-788-60- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (55700-788-60)

55700- Quality Care Products, LLC
- 55700-806- Oxymorphone hydrochloride
  - 55700-806-60- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (55700-806-60)

60951- Par Pharmaceutical
- 60951-794- Oxymorphone Hydrochloride
  - 60951-794-70- 100 TABLET in 1 BOTTLE (60951-794-70)

60951- Par Pharmaceutical
- 60951-795- Oxymorphone Hydrochloride
  - 60951-795-70- 100 TABLET in 1 BOTTLE (60951-795-70)

63481- Endo Pharmaceuticals Inc.
- 63481-612- OPANA
  - 63481-612-70- 100 TABLET in 1 BOTTLE (63481-612-70)

63481- Endo Pharmaceuticals Inc.
- 63481-613- OPANA
  - 63481-613-70- 100 TABLET in 1 BOTTLE (63481-613-70)

63481- Endo Pharmaceuticals Inc.
- 63481-812- Opana ER
  - 63481-812-60- 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (63481-812-60)

63481- Endo Pharmaceuticals Inc.
- 63481-814- Opana ER
  - 63481-814-60- 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (63481-814-60)

63481- Endo Pharmaceuticals Inc.
- 63481-815- Opana ER
  - 63481-815-60- 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (63481-815-60)

64896- Amneal Pharmaceuticals LLC
- 64896-695- Oxymorphone hydrochloride
  - 64896-695-01- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-695-01)

64896- Amneal Pharmaceuticals LLC
- 64896-695- Oxymorphone hydrochloride
  - 64896-695-03- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-695-03)

64896- Amneal Pharmaceuticals LLC
- 64896-695- Oxymorphone hydrochloride
  - 64896-695-08- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-695-08)

64896- Amneal Pharmaceuticals LLC
- 64896-695- Oxymorphone hydrochloride
  - 64896-695-13- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-695-13)

64896- Amneal Pharmaceuticals LLC
- 64896-696- Oxymorphone hydrochloride
  - 64896-696-01- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-696-01)

64896- Amneal Pharmaceuticals LLC
- 64896-696- Oxymorphone hydrochloride
  - 64896-696-03- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-696-03)

64896- Amneal Pharmaceuticals LLC
- 64896-696- Oxymorphone hydrochloride
  - 64896-696-08- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-696-08)

64896- Amneal Pharmaceuticals LLC
- 64896-696- Oxymorphone hydrochloride
  - 64896-696-13- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-696-13)

64896- Amneal Pharmaceuticals LLC
- 64896-697- Oxymorphone hydrochloride
  - 64896-697-01- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-697-01)

64896- Amneal Pharmaceuticals LLC
- 64896-697- Oxymorphone hydrochloride
  - 64896-697-03- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-697-03)

64896- Amneal Pharmaceuticals LLC
- 64896-697- Oxymorphone hydrochloride
  - 64896-697-08- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-697-08)

64896- Amneal Pharmaceuticals LLC
- 64896-697- Oxymorphone hydrochloride
  - 64896-697-13- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-697-13)

64896- Amneal Pharmaceuticals LLC
- 64896-698- Oxymorphone hydrochloride
  - 64896-698-01- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-698-01)

64896- Amneal Pharmaceuticals LLC
- 64896-698- Oxymorphone hydrochloride
  - 64896-698-03- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-698-03)

64896- Amneal Pharmaceuticals LLC
- 64896-698- Oxymorphone hydrochloride
  - 64896-698-08- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-698-08)

64896- Amneal Pharmaceuticals LLC
- 64896-698- Oxymorphone hydrochloride
  - 64896-698-13- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-698-13)

64896- Amneal Pharmaceuticals LLC
- 64896-699- Oxymorphone hydrochloride
  - 64896-699-01- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-699-01)

64896- Amneal Pharmaceuticals LLC
- 64896-699- Oxymorphone hydrochloride
  - 64896-699-03- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-699-03)

64896- Amneal Pharmaceuticals LLC
- 64896-699- Oxymorphone hydrochloride
  - 64896-699-08- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-699-08)

64896- Amneal Pharmaceuticals LLC
- 64896-699- Oxymorphone hydrochloride
  - 64896-699-13- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-699-13)

64896- Amneal Pharmaceuticals LLC
- 64896-700- Oxymorphone hydrochloride
  - 64896-700-01- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-700-01)

64896- Amneal Pharmaceuticals LLC
- 64896-700- Oxymorphone hydrochloride
  - 64896-700-03- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-700-03)

64896- Amneal Pharmaceuticals LLC
- 64896-700- Oxymorphone hydrochloride
  - 64896-700-08- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-700-08)

64896- Amneal Pharmaceuticals LLC
- 64896-700- Oxymorphone hydrochloride
  - 64896-700-13- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-700-13)

64896- Amneal Pharmaceuticals LLC
- 64896-701- Oxymorphone hydrochloride
  - 64896-701-01- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-701-01)

64896- Amneal Pharmaceuticals LLC
- 64896-701- Oxymorphone hydrochloride
  - 64896-701-03- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-701-03)

64896- Amneal Pharmaceuticals LLC
- 64896-701- Oxymorphone hydrochloride
  - 64896-701-08- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-701-08)

64896- Amneal Pharmaceuticals LLC
- 64896-701- Oxymorphone hydrochloride
  - 64896-701-13- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64896-701-13)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Contr. Subst. Schedule ⬆ ⬇

Code ⬆